Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-04-30

Development of a novel multiple automated DNA synthesizer (for 10-25 oligos simultaneously) allowing production of large number of inexpensive oligonucleotides for application in clinics and diagnostics

Objective

Construction and demonstration of a multiple DNA sythesizer prototype to enable diagnostic laboratories to produce many nucleotides simultaneously, on a user friendly simply operated device cost reduction for synthesis of oligonucleotides for clinical and diagnostic purposes. to provide molecular diagnostic tools for clinical applications, e.g.: fluorescent and chemiluminescent based systems for the diagnosis of neurodegenerative disorders due to CAG-repeat expansions reverse dot-blot chemiluminescent based systems for the diagnosis of cystic fibrosis in the different regions of Europe. Production of cheap dye-labelled microsatellite marker sets for automatic genetic mapping of the human genome. Analysis of mutations occuring during tumour development, devising new medical treatment and identifying risk factors.

Clinical laboratories will need synthesizers which can produce many different oligonucleotides simultaneously, in a fast and inexpensive way. The current standard synthesis technology is limited to synthesis of 3-4 oligonucleotides simultaneously The high price per oligonucleotide renders extensive clinical analyses expensive. Today's synthesis chemistry and synthesizer technology are not suited to meet future demands. To meet these demands fast multiple DNA synthesizers resulting in low cost oligonucleotides, are required. Based on the concept of the EMBL synthesizer the production of an industrial prototype of a 10 column device, with optional upscaling to 25-40 columns, is one main goal of the project. The technology will reduce DNA synthesis costs by a factor of 10, while increasing the throughput by nearly an order of magnitude compared to standard commercial devices. Among the use of oligonucleotides as a diagnostic tool the most important is their role in PCR as primers for the amplification of specific loci as the previous step in the analysis a given gene or region of the genome. The scope of PCR in clinical diagnosis covers mainly genetic disorders, infectious diseases, and cancer. In the field of infectious diseases, we are entering a period where the diagnosis is becoming more and more molecular, based on the use of PCR and oligonucleotide sequences. The performance of the new synthesizer in molecular medicine will be demonstrated in activities resulting in molecular diagnostic tools for several clinical applications: a) Fluorescent and chemiluminescent based systems for the diagnosis of neurodegenerative disorders due to CAG-repeat expansions. b) Reverse dot-blot chemiluminescent based systems for the diagnosis of cystic fibrosis in the different regions of Europe. c) Inexpensive dye-labelled microsatellite marker sets for automatic genetic mapping of the human genome. cl) Analysis of mutations occurring during tumour development, devising new medical treatment and identifying risk factors.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

Data not available

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CSC - Cost-sharing contracts

Coordinator

EUROPEAN MOLECULAR BIOLOGY LABORATORY
EU contribution
No data
Address
Meyerhofstrasse 1
69117 HEIDELBERG
Germany

See on map

Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (3)

My booklet 0 0